Solana (NASDAQ:HSDT) Posts Earnings Results, Misses Estimates By $0.96 EPS

Solana (NASDAQ:HSDT) released its quarterly earnings results on Friday. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.96), FiscalAI reports. Solana had a negative net margin of 679.54% and a negative return on equity of 104.96%. The business had revenue of $3.62 million during the quarter, compared to the consensus estimate of $3.40 million.

Here are the key takeaways from Solana’s conference call:

• Solana Company said first-quarter revenue rose to $3.6 million from just $49,000 a year ago, driven mainly by $3.4 million of staking revenue. Management framed this as early validation of its digital asset treasury strategy.
• The company reported a net loss of $99.8 million, largely due to non-cash markdowns tied to the roughly 33% decline in SOL during the quarter. It also recorded an $89.2 million unrealized loss on digital assets and receivables.
• Management highlighted 6.9% average net staking yield in Q1, above the estimated system-wide average of about 6.0%. They said this outperformance came from validator selection, MEV capture, and active rebalancing.
• The company completed an $8 million strategic equity raise in late April at a price described as about 1.1x NAV, and said part of the proceeds was used to buy SOL at attractive levels. Management called the raise immediately accretive to SOL per share.
• Solana Company is expanding beyond treasury management into advisory services, validator infrastructure, and an AI-powered platform, with initial validator nodes expected to go live in late June. Management also said it completed the divestiture of its medical device business, which should help reduce future costs.

Solana Stock Performance

NASDAQ:HSDT traded down $0.09 on Friday, hitting $2.30. 147,829 shares of the stock were exchanged, compared to its average volume of 216,834. The stock has a market capitalization of $126.25 million, a price-to-earnings ratio of 0.00 and a beta of 1.06. Solana has a 52 week low of $1.59 and a 52 week high of $258.50. The company’s 50-day moving average price is $2.06 and its 200 day moving average price is $2.92.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on HSDT shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Solana in a report on Tuesday, April 21st. Maxim Group started coverage on Solana in a report on Monday, April 6th. They issued a “buy” rating and a $4.00 price target for the company. B. Riley Financial started coverage on Solana in a report on Thursday, April 23rd. They issued a “buy” rating and a $3.00 price target for the company. Finally, Zacks Research raised Solana to a “hold” rating in a report on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $3.50.

Institutional Trading of Solana

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. LPL Financial LLC raised its holdings in Solana by 120.1% during the 4th quarter. LPL Financial LLC now owns 382,255 shares of the company’s stock worth $1,105,000 after purchasing an additional 208,558 shares during the last quarter. Geode Capital Management LLC bought a new stake in Solana during the 4th quarter worth about $1,006,000. State Street Corp bought a new stake in Solana during the 4th quarter worth about $464,000. Cetera Investment Advisers bought a new stake in Solana during the 4th quarter worth about $347,000. Finally, Marshall Wace LLP bought a new stake in Solana during the 4th quarter worth about $195,000. 18.63% of the stock is owned by institutional investors.

About Solana

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non?invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.